Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model

Nature Medicine

Volumn 15, Issue 6, 2009, Pages 690-695

  Malicdan, May Christine V ^a,b   Noguchi, Satoru ^a   Hayashi, Yukiko K ^a   Nonaka, Ikuya ^a   Nishino, Ichizo ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; N ACETYLMANNOSAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISTAL MYOPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; LOW DRUG DOSE; MOUSE; MUSCLE ATROPHY; MUSCLE WEAKNESS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MUSCULAR DISEASES; N-ACETYLNEURAMINIC ACID; PHENOTYPE;

EID: 67349234199     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1956     Document Type: Article

References (35)

1. Nonaka, I., Noguchi, S. & Nishino, I. Distal myopathy with rimmed vacuoles and hereditary inclusion body myopathy. Curr. Neurol. Neurosci. Rep. 5, 61-65 (2005).
2. Nishino, I. et al. Molecular pathomechanism of distal myopathy with rimmed vacuoles. Acta Myol. 24, 80-83 (2005).
3. Tsuruta, Y. et al. Expression of the lysosome-associated membrane proteins in myopathies with rimmed vacuoles. Acta Neuropathol. 101, 579-584 (2001).
4. Malicdan, M.C., Noguchi, S. & Nishino, I. Autophagy in a mouse model of distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Autophagy 3, 396-398 (2007).
5. Askanas, V. & Engel, W.K. Hereditary inclusion myopathies. in. The molecular and genetic basis of neurologic and psychiatric disease (eds. Rosenberg, R.N., Prusiner, S.B., DiMauro, S., Barchi, R.L. & Nestler, E.J.) 501-509 (Butterworth-Heinemann, Woburn, Massachusetts, 2003).
6. Eisenberg, I. et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat. Genet. 29, 83-87 (2001).
7. Ikeuchi, T. et al. Gene locus for autosomal recessive distal myopathy with rimmed vacuoles maps to chromosome 9. Ann. Neurol. 41, 432-437 (1997).
8. Nishino, I. et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology 59, 1689-1693 (2002).
9. Keppler, O.T. et al. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science 284, 1372-1376 (1999).
10. Krause, S. et al. Localization of UDP-GlcNAc 2-epimerase/ManAc kinase (GNE) in the Golgi complex and the nucleus of mammalian cells. Exp. Cell Res. 304, 365-379 (2005).
11. Wang, Z., Sun, Z., Li, A.V. & Yarema, K.J. Roles for GNE outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation and apoptosis, and ERK1/2 phosphorylation. J. Biol. Chem. 281, 27016-27028 (2006).
12. Amsili, S. et al. UDP-N-acetylglucosamine 2-epimerase/N- acetylmannosamine kinase (GNE) binds to α-actinin 1: novel pathways in skeletal muscle? PLoS One 3, e2477 (2008).
13. Noguchi, S. et al. Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J. Biol. Chem. 279, 11402-11407 (2004).
14. Broccolini, A. et al. Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle. J. Neurochem. 105, 971-981 (2008).
15. Malicdan, M.C., Noguchi, S., Nonaka, I., Hayashi, Y.K. & Nishino, I. A Gne knockout mouse expressing human GNE D176V mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Hum. Mol. Genet. 16, 2669-2682 (2007).
16. Malicdan, M.C., Noguchi, S., Hayashi, Y.K. & Nishino, I. Muscle weakness correlates with muscle atrophy and precedes the development of inclusion body or rimmed vacuoles in the mouse model of DMRV/hIBM. Physiol. Genomics 35, 106-115 (2008).
17. Comb, D.G. & Roseman, S. Composition and enzymatic synthesis of N-acetylneuraminic (sialic) acid. J. Am. Chem. Soc. 80, 497-499 (1958).
18. Thomas, G.H., Scocca, J., Miller, C. & Reynolds, L.W. Accumulation of N-acetylneuraminic acid (sialic acid) in human fibroblasts cultured in the presence of N-mannosamine. Biochim. Biophys. Acta 846, 37-43 (1985).
19. Galeano, B. et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J. Clin. Invest. 117, 1585-1594 (2007).
20. Robitaille, G., Ng-Kwai-Hang, K.F. & Monardes, H.G. Association of k-casein glycosylation with milk production and composition in holsteins. J. Dairy Sci. 74, 3314-3317 (1991).
21. Clarke, B.A. et al. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376-385 (2007).
22. Kabeya, Y. et al. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J. Cell Sci. 117, 2805-2812 (2004).
23. Mizushima, N. & Yoshimori, T. How to interpret LC3 immunoblotting. Autophagy 3, 542-545 (2007).
24. Kumamoto, T. et al. Proteasomes in distal myopathy with rimmed vacuoles. Intern. Med. 37, 746-752 (1998).
25. Corfield, A.P. & Schauer, R. Occurrence of sialic acids. in Sialic Acids. Chemistry, Metabolism, and Function (ed. Schauer, R.) 5-50 (Springer, Wien, New York, 1982).
26. Helenius, A. How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum. Mol. Biol. Cell 5, 253-265 (1994).
27. Iijima, R., Takahashi, H., Namme, R., Ikegami, S. & Yamazaki, M. Novel biological function of sialic acid (N-acetylneuraminic acid) as a hydrogen peroxide scavenger. FEBS Lett. 561, 163-166 (2004).
28. Askanas, V. & Engel, W.K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition. Neurology 66 (suppl 1), S39-S48 (2006).
29. Spuler, S. et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann. Neurol. 63, 323-328 (2008).
30. Lynch, G.S., Hinkle, R.T., Chamberlain, J.S., Brooks, S.V. & Faulkner, J. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J. Physiol. (Lond.) 535, 591-600 (2001).
31. Malicdan, M.C., Noguchi, S. & Nishino, I. Monitoring autophagy in muscle disaseases. Methods Enzymol. 453, 379-396 (2009).
32. Gagiannis, D., Gossrau, R., Reutter, W., Zimmermann-Kordmann, M. & Horstkorte, R. Engineering the sialic acid in organs of mice using N-propanoylmannosamine. Biochim. Biophys. Acta 1770, 297-306 (2007).
33. Hara, S. et al. Determination of mono-O-acetylated N-acetylneuraminic acids in human and rat sera by fluorometric high-performance liquid chromatography. Anal. Biochem. 179, 162-166 (1989).
34. Schmidt, S., Jiang, Y., Nixon, R. & Mathews, P. Amyloid proteins methods and protocol. in. Methods in Molecular Biology Vol. 299 (ed. Sigurdsson, E.M.) 408 (Humana Press, New York, 2004).
35. Kotani, K., Maekawa, M. & Kanno, T. Reestimation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio based on JSCC consensus method -changes of criteria for a differential diagnosis of hepatic disorders following the alteration from Karmen method to JSCC method [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 91, 154-161 (1994).